Completed OBSERVATIONAL NCT00935870

Bioactive Glass as Bone Graft Substitute in Operative Treatment of Bone - a 10 Years Follow-up Study

Bioactive Glass (S53P4) as Bone Graft Substitute in Operative Treatment of Depressed Lateral Condyle Fractures, Benign Bone Tumour Cavities and in Spinal Fusion - a 10 Years Follow-up and Bone Density Study.

Sponsor: Vivoxid Ltd

Conditions Benign Bone Tumour Cavity Depressed Lateral Condyle Fracture Spinal Fusion

Interventions Bioactive glass and/or autogenous bone

Updated 6 times since 2017 Last updated: Jul 8, 2009 Started: Jan 31, 2008 Primary completion: Jun 30, 2008 Completion: Feb 28, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00935870, this observational or N/A phase trial focuses on Benign Bone Tumour Cavity and Depressed Lateral Condyle Fracture and remains completed. Sponsored by Vivoxid Ltd, it has been updated 6 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vivoxid Ltd

Data source: Vivoxid Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Turku, Finland